Tyra Biosciences, Inc. (TYRA) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

49/ 100

GoAI Score

Hold

Valuation

39

Expensive

Sentiment

70

Bullish

Risk

48

Elevated Risk

Momentum

65

Gaining

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Todd Harris
Listed since: Sep 15, 2021
Employees: 87

Market position

Day range

Current $19.97

$19.50$20.16

52-week range

Current $19.97

$13.29$40.65

Open: $20.11
Previous close: $20.39
Volume: 792.25K; 0.86× average
Average volume: 921.32K; Average daily volume
Market cap: 1.19B USD
Beta: 0.75; Market reference 1
50-day average: $25.2586; -20.94% below average
200-day average: $30.4721; -34.46% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.5B USD
P/E (TTM): -8.32×
P/B (TTM): 3.73×
P/S (TTM): 0×
EV / EBITDA: -12.52×
Earnings yield: -7.65%
Free cash flow yield: -6.08%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -46.28%
Return on assets: -42.44%
Return on invested capital: -50.10%

Financial health

Debt / equity: 0.02×
Current ratio: 14.67×
Altman Z-score: 22.7
Piotroski F-score: 1 of 9

Financial statements

Income trends

Operating income

−132.76M USD-27.44%

Net income

−119.95M USD-38.70%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	102.93M USD	80.08M USD	62.52M USD	43.01M USD	20.64M USD
Selling, general, and administrative	29.83M USD	24.1M USD	17.43M USD	15.92M USD	5.65M USD
Operating expenses	132.76M USD	104.18M USD	79.95M USD	58.93M USD	26.29M USD
Interest income	12.82M USD	17.7M USD	10.81M USD	3.65M USD	13K USD
Depreciation and amortization	546K USD	519K USD	357K USD	296K USD	140K USD
Operating income	−132.76M USD	−104.18M USD	−79.95M USD	−58.93M USD	−26.29M USD
Net income	−119.95M USD	−86.48M USD	−69.13M USD	−55.33M USD	−26.29M USD

Company facts updated Oct 8, 2026.

Earnings

EPS beat rate: 45%; 5 beats, 5 misses, 1 met estimate
Average EPS surprise: +3.67%; 11 comparable reports
Latest EPS result: -0.69; Estimate -0.65 · Miss by 6.17%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$45.17

126.19% upside

Past 12 months12-month forecastHigh $56.00Average $45.17Low $29.00

Rating distribution

7 ratings

Strong buy00%

Buy7100%

Hold00%

Sell00%

Strong sell00%

Recent analyst actions

6 institutions

JefferiesmaintainBuyFeb 3, 2026

TYRA news

prnewswire.comOct 8, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA). Such investors are advised to contact Danielle…

Read source

globenewswire.comOct 6, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or the “Company”) (NASDAQ: TYRA). Such investors are advised to contact Danielle…

Read source

prnewswire.comOct 1, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA). Such investors are advised to contact Danielle…

Read source

globenewswire.comSep 29, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or the “Company”) (NASDAQ: TYRA). Such investors are advised to contact Danielle…

Read source

defenseworld.netSep 25, 2026

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89

Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen research firms that are covering the stock, Marketbeat reports. One investment…

Read source

prnewswire.comSep 17, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).

Read source